CYTK
CYTOKINETICS INC
NASDAQ · Healthcare · Biotechnology · US
$68.78
−1.63%0
Insider buys (3m)
21
Insider sells (3m)
-$18.9M
Net value (3m)
-13.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Landry Robert E · director | Sale | 1,000 | $72 |
| Sep 15, 2026 | Blum Robert I · director, officer: President & CEO | Sale | 7,500 | $73 |
| Sep 15, 2026 | Blum Robert I · director, officer: President & CEO | Sale | 97,926 | $69 |
| Sep 15, 2026 | Blum Robert I · director, officer: President & CEO | M-Exempt | 7,500 | $11 |
| Sep 11, 2026 | Landry Robert E · director | Sale | 1,000 | $75 |
| Sep 8, 2026 | Malik Fady Ibraham · officer: EVP Research & Development | Sale | 3,500 | $75 |
| Sep 8, 2026 | Malik Fady Ibraham · officer: EVP Research & Development | M-Exempt | 3,500 | $7.80 |
| Sep 1, 2026 | PARSHALL B LYNNE · director | Sale | 5,000 | $71 |
| Aug 31, 2026 | Callos Andrew · officer: EVP, Chief Commercial Officer | Sale | 10,000 | $70 |
| Aug 31, 2026 | Blum Robert I · director, officer: President & CEO | M-Exempt | 7,500 | $11 |
| Aug 31, 2026 | Callos Andrew · officer: EVP, Chief Commercial Officer | M-Exempt | 10,000 | $23 |
| Aug 31, 2026 | Blum Robert I · director, officer: President & CEO | Sale | 7,500 | $70 |
| Aug 18, 2026 | Malik Fady Ibraham · officer: EVP Research & Development | Sale | 3,500 | $76 |
| Aug 18, 2026 | Malik Fady Ibraham · officer: EVP Research & Development | M-Exempt | 3,500 | $7.80 |
| Aug 10, 2026 | Blum Robert I · director, officer: President & CEO | M-Exempt | 7,500 | $11 |
| Aug 10, 2026 | Blum Robert I · director, officer: President & CEO | Sale | 7,500 | $77 |
| Jul 30, 2026 | Callos Andrew · officer: EVP, Chief Commercial Officer | M-Exempt | 14,000 | $23 |
| Jul 30, 2026 | Callos Andrew · officer: EVP, Chief Commercial Officer | Sale | 14,000 | $80 |
| Jul 27, 2026 | Blum Robert I · director, officer: President & CEO | M-Exempt | 7,500 | $11 |
| Jul 27, 2026 | Blum Robert I · director, officer: President & CEO | Sale | 7,500 | $81 |
| Jul 23, 2026 | Malik Fady Ibraham · officer: EVP Research & Development | Sale | 3,500 | $81 |
| Jul 23, 2026 | Malik Fady Ibraham · officer: EVP Research & Development | M-Exempt | 3,500 | $7.80 |
| Jul 16, 2026 | Kaye Edward M. MD · director | A-Award | 151 | $83 |
| Jul 16, 2026 | Harrington Robert Arthur · director | A-Award | 151 | $83 |
| Jul 16, 2026 | WIERENGA WENDELL · director | A-Award | 75 | $83 |
| Jul 16, 2026 | Daly James M · director | A-Award | 151 | $83 |
| Jul 16, 2026 | Wysenski Nancy · director | A-Award | 75 | $83 |
| Jul 16, 2026 | HENDERSON JOHN T · director | A-Award | 272 | $83 |
| Jul 14, 2026 | Blum Robert I · director, officer: President & CEO | M-Exempt | 7,490 | $11 |
| Jul 14, 2026 | Blum Robert I · director, officer: President & CEO | Sale | 7,490 | $82 |
Institutional positioning
13F filings over the trailing two quarters
New 174Increased 421Reduced 247Sold out 51
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 20,094,362 | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | Increased | 18,718,498 | Aug 14, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Reduced | 17,523,840 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 16,548,011 | May 13, 2026 |
| FMR LLC | Reduced | 10,723,140 | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 8,009,489 | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 6,931,770 | Aug 14, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 6,711,799 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 6,494,233 | Aug 7, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 6,117,515 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 5,843,782 | May 8, 2026 |
| STATE STREET CORP | Reduced | 5,745,193 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 5,488,634 | May 15, 2026 |
| FMR LLC | Reduced | 5,031,782 | Aug 13, 2026 |
| Avoro Capital Advisors LLC | Increased | 4,999,999 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 15, 2026